AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?

AstraZeneca (AZN) stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca’s stock has also outperformed the sector as well as the S&P 500 index, as seen in the chart below. The stock has also been trading above its 200-day moving average since mid-March.AstraZeneca Stock Outperforms Industry, Sector & S&PImage Source: Zacks Investment ResearchAstraZeneca has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinz ...